Abstract��
OBJECTIVE To compare the efficacy and safety of bevacizumab plus FOLFIRI program or FOLFOX program for metastatic colorectal cancer. METHODS From January 2012 to March 2013, FOLFIRI program plus bevacizumab (group A, 19 cases) and FOLFOX program plus bevacizumab (group B, 23 cases) were collected. Effective rate, adverse reaction, tumor markers before and after treatment and following-up situation changes were analyzed retrospectively between two groups. RESULT Effective rates were 26.3% and 39.1% in group A and group B. Disease control rate were 84.2% and 82.6% in group A and in group B. Before and after treatment, the concentration of tumor markers of all patients changed insignificantly (P>0.05). There were not statistically difference between two groups (P>0.05). Adverse events of two groups were ��-��degree, no serious adverse reactions occurred, the difference was not statistically significant (P>0.05). CONCLUSION FOLFIRI program plus bevacizumab and FOLFOX program plus bevacizumab for treatment of metastatic colorectal cancer have good results, the result of group B is better, and the majority of adverse reactions are mild to moderate and not all the same. Both programs have the tolerable toxic side-effects.
PEI Bao-Xiang-,
ZHANG Zi-Yang-,
XU Yan-Ping-*
.Clinical Research of Bevacizumab Plus Different Kinds of Chemotherapieutics for Metastatic Colorectal Cancer[J] Chinese Pharmaceutical Journal, 2014,V49(22): 2039-2042
��
[1]
WAN D S, CHEN G.The recent research developments in epidemiology and risk factors of colorectal cancer[J]. Prac J Cancer(ʵ�ð�֢��־), 2000, 15 (2):220-222.[2] LIU K J, ZHENG Y B, TONG S L,et al. Clinical research of bevacizumab plus chemotherapy for advanced metastatic colorectal cancer[J]. Chin J Gastroenterol Hepatol (θ����ѧ�β�ѧ��־), 2011,20(10):900-903.[3] MAO H, SHI Y, DAI G G. Clinical observation of cetuximab plus FOLFOX 4 regimen as the first-line treatment for patients with metastatic colorectal cancer[J]. Chin Clin Oncology (�ٴ�����ѧ��־), 2012, 17(4):356-359.[4] FOLKMAN J.Tumor angiogenesis therapeutic implications[J].N Engl J Med, 1971,285(21): 1182-1190.[5] LI Y, HU X, CHENG G, et al. Pharmacokinetic study of recombinant Humanized bevacizumab in Chinese subjects with advanced malignancies[J]. Chin Pharm J(�й�ҩѧ��־), 2010,45(22):1749-1752.[6] QIU Y B, LU Y, WU H B, et al. The adverse reaction of bevacizumab and combined chemotherapy in treatment[J]. Adv Drug React J (ҩ�ﲻ����Ӧ��־),2006,8(6):434-433.[7] HURWITZ H, FEHRENBACHER L, NOVOTNY W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350(23): 2335- 2342.[8] HU Y Q, ZHANG Y B, LI X, et al. Oxaliplatin into combined chemotherapy in treatment of advanced colorectal cancer recent curative effect and safety observation[J].J China Pharm (�й�ҩ��), 2011,22(4):331-332.[9] BAI F T. The recent development in the treatment of advanced colorectal cancer drugs[J].J North China Coal Med Sci (����ú̿ҽѧԺѧ��), 2011,13(2):172-174.[10] SONG Y M, LIAN C G, XI X. Multiple tumor markers protein chip of the research in the diagnosis of colon cancer[J]. J Changzhi Med Coll(����ҽѧԺѧ��), 2012,26(1):34-38.[11] HUANG J, LI T, ZHOU K Y, et al. Serum tumor markers[J]. Chem Life(�����Ļ�ѧ), 2010,30(4):567-570.[12] DONG Y F. Detection and application of tumor markers[J]. Chin J Birth Health Heredity (�й��������Ŵ���־), 2011,19(2):126-127.[13] JIANG W R, LIU J. The developments of chemotherapy of colorectal cancer[J].China Cancer(�й�����), 2011,20(3):200-203.[14] LIU S Y,WANG X J. Bevacizumab related adverse reaction in antineoplastic therapy[J].J Oncology (����ѧ��־),2009,15(12):1133-1135.
2014, Vol. 49 
